Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pfizer
Biotech
Pfizer axes oral GLP-1 asset, blowing hole in obesity plan
Pfizer axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial.
Nick Paul Taylor
Apr 14, 2025 7:34am
Pfizer sells San Diego R&D site for $255M
Apr 10, 2025 11:06am
A closer look at pharma's top R&D budgets
Apr 4, 2025 9:34am
Pfizer, Flagship turn to autoimmune for latest angle of collab
Apr 1, 2025 9:38am
Top 10 pharma R&D budgets in 2024
Mar 31, 2025 6:00am
Pfizer, Arvinas' PROTAC posts mixed results in first ph. 3 test
Mar 11, 2025 10:06am
